© 2020 MJH Life Sciences and HCPLive. All rights reserved.
August 12, 2020
Less than 1% of nearly 500,000 hospitalized patients required kidney replacement therapy.
July 23, 2020
Canagliflozin is a known treatment for kidney disease, as well as heart failure in patients with type 2 diabetes and diabetic nephropathy.
July 17, 2020
There is a higher chronic kidney disease prevalence for individuals with lower educational levels.
July 15, 2020
Chronic kidney disease and kidney failure represent the most common comorbidities for patients hospitalized with COVID-19 infections.
The estimated two-year four-variable kidney failure risk equation for individual risk using predicted ACR from PCR had discrimination similar to that of using observed ACR.
June 13, 2020
Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.
April 10, 2020
New research is shining light on the use of eGFR as a biomarker for increased cardiovascular risk.
March 27, 2020
The intravenous approach can be used regardless of what bicarbonate delivery method a dialysis center uses.
March 21, 2020
A discussion with a Brigham and Women's Hospital cardiologist on the research of the add-on cardiometabolic drug class.
February 19, 2020
Azathioprine is linked to a slightly higher eGFR for patients with inflammatory bowel disease.